Levosimendan Versus Dobutamine in Shock Patients
Information source: Wentworth Area Health Services
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiogenic Shock; Septic Shock
Intervention: Levosimendan (Drug); Dobutamine (Drug)
Phase: Phase 2/Phase 3
Status: Recruiting
Sponsored by: Wentworth Area Health Services
Summary
The purpose of the study is to compare the efficacy of levosimendan with that of dobutamine
in patients with unstable hemodynamics (shock).
Clinical Details
Official title: Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Resolution of shock state
Secondary outcome: Change in cardiac functions
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Reduced left ventricular systolic function
- Hypotension
- Anuria or oligouria
Exclusion Criteria:
- Less than 18 years old
- Pregnant
- Uncorrected valvular stenosis
- Hypertrophic obstructive cardiomyopathy (HOCM)
- Third degree AV block
Locations and Contacts
Intensive Care Unit, Nepean Hospital, Penrith, New South Wales 2750, Australia; Recruiting Anthony S McLean, MD, Phone: +61-2-47342490, Email: mcleana@wahs.nsw.gov.au Stephen J Huang, PhD, Phone: +61-247342320, Email: huangs@wahs.nsw.gov.au Anthony S McLean, MD, Principal Investigator Stephen J Huang, PhD, Sub-Investigator Ian Seppelt, MD, Sub-Investigator Marek Nalos, MD, Sub-Investigator
Additional Information
Starting date: October 2004
Last updated: June 23, 2005
|